Vertex Pharmaceuticals Incorporated (VRTX) NASDAQ

388.05

+0.9(+0.23%)

Updated at September 18 02:06PM

Currency In USD

Vertex Pharmaceuticals Incorporated

Address

50 Northern Avenue

Boston, MA 02210

United States of America

Phone

617 341 6100

Sector

Healthcare

Industry

Biotechnology

Employees

6100

First IPO Date

July 24, 1991

Key Executives

NameTitlePayYear Born
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director6.54M1973
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman70,0001956
Dr. Ourania Tatsis Ph.D.Executive Vice President and Chief Regulatory & Quality Officer2.08M1970
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer2.39M1965
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial Officer2.75M1968
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating Officer3.15M1966
Ms. Susie Lisa C.F.A.Senior Vice President of Investor Relations0N/A
Ms. Kristen C. Ambrose CPASenior Vice President & Chief Accounting Officer01977
Mr. Jonathan Biller J.D.Executive Vice President & Chief Legal Officer01965
Ms. Nina DevlinSenior Vice President & Chief Communications Officer0N/A

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.